26 June 2019 · Advice on the use of Patient Group Directions (PGDs) to supply or administer a medication which is part of a clinical trial, study or pilot
29 June 2022 · Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance
29 June 2022 · Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
9 September 2020 · Advice on the legal labelling requirements for Prescription Only Medicines and Pharmacy Medicines supplied under a patient group direction or legal exemption.
2 August 2024 · Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
2 August 2024 · Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
16 July 2024 · Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.